{
  "docId": "019de073-a59c-77cf-8e75-229e6c5c9530",
  "docSlug": "74412512a1adb89488775a4a2b6a1b7b",
  "documentTitle": "Avenue Therapeutics | IPO Presentation Deck | 30 slides",
  "authorId": "avenue-therapeutics",
  "authorName": "Avenue Therapeutics",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 11,
  "pageCount": 30,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/11",
  "deckHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530",
  "deckJsonHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json",
  "deckAnchorHref": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.92,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "Disease: Epilepsy is a chronic disease that manifests as recurrent seizures from abnormal electrical discharge in the brain; Affects approximately 65M patients worldwide",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e17258ba-389e-4aaf-bac6-25674b5199cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.92,
        "x": 0.04,
        "y": 0.69
      },
      "kind": "list",
      "text": "Unmet Need: ~50% of epilepsy patients fail 1st line treatments and ~30% of patients are not well managed with any antiseizure medications; BZDs are effective for seizures, but not well tolerated due to significant side effects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4973c30-4e00-49d5-9883-1cfec6baeb53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.92,
        "x": 0.04,
        "y": 0.44
      },
      "kind": "list",
      "text": "Treatment: Standard of care is the use of one or more anti-epileptic drugs (AED); Benzodiazepines (BZDs) are a class of AED that are used to treat seizures, but are generally not used as daily medication due to side effects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa637344-03e0-40f1-aedc-934a5734bb35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.16,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: CDC.gov; Kalilani L et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018 Dec",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27761d21-8684-47fa-9e8c-775d37c8cfa6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Epilepsy patients are prescribed benzodiazepines to control seizures, but have significant unmet needs for therapies with improved safety profiles",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef757212-f3cc-43e9-8375-76b082ac07f5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 11,
      "beatId": "5260138e-00d3-4228-841b-29589c8a9035",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "Slides 11 and 12 present the problem statement, highlighting the unmet needs in epilepsy and acute anxiety treatment.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e6485657-8caf-4343-bf92-1e9c148fd1b1",
      "evidence": "The loop is opened on slide 11, highlighting the limitations of current treatments, and closed on slide 14, presenting BAER-101 as a solution.",
      "position": 0,
      "objective": "What are the consequences of not addressing the unmet needs in epilepsy and acute anxiety treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}